Osimertinib as a Potential Targeted Therapy for Non-Small Cell Lung Carcinoma (NSCLC) Patients with EGFR Exon 20 T790M

Nur Zam Zam, Harun Iskandar, Nur Ahmad Tabri, Arif Santoso, Nurjannah Lihawa, Harry Akza Putrawan, Ferry Sandra


BACKGROUND: Emergence of drug resistance due to epidermal growth factor receptor (EGFR) Exon 20 T790M poses a challenge in the effective management of non-small cell lung carcinoma (NSCLC). Significant breakthrough in the management of NSCLC with a specific genetic alteration causes substantial condition improvement in patients whose cancer progressed after first-generation tyrosine kinase inhibitor treatment and who developed tumors with EGFR Exon 20 T790M mutation. The present study analyzed a cohort of NSCLC patients and investigated the incidence of the EGFR Exon 20 T790M status with Osimertinib therapy, along with its impact on survival rates.

METHODS: This was a retrospective cohort study on 22 NSCLC subjects who were genetically examined for EGFR status from plasmic cell free total nucleic acid. Subjects with EGFR Exon 20 T790M mutation were treated with/without Osimertinib. Demographic and clinical data were descriptively summarized, and the differences of each variable and correlation between survival rate and EGFR Exon 20 T790M were analyzed.

RESULTS: Subjects with (n=13) and without (n=9) EGFR Exon 20 T790M had survival rates of 10.77±2.45 and 4.78±1.48, respectively (p=0.000). Based on 1-year survival status of subjects with EGFR Exon 20 T790M, there were 3 Osimertinib-treated survivors and 2 Osimertinib-treated non-survivors. Eight subjects with EGFR Exon 20 T790M and without Osimertinib treatment did not survive (p=0.001).

CONCLUSION: Since the treatment of Osimertinib demonstrated a noteworthy survival rate among NSCLC subjects with EGFR Exon 20 T790M, thus Osimertinib could be suggested as a potential targeted therapy for NSCLC subjects with EGFR Exon 20 T790M.

KEYWORDS: non-small cell lung carcinoma, EGFR, Exon 20, T790M, osimertinib


Full Text:



Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res. 2021; 167: 105583, CrossRef.

Hsu WH, Yang JH, Mok T, Loong H. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018; 29: i3-9, CrossRef.

Izumi M, Suzumura T, Ogawa K, Matsumoto Y, Sawa K, Yoshimoto N, et al. Differences in molecular epidemiology of lung cancer among ethnicities (Asian vs. Caucasian). J Thorac Dis. 2020; 12(7): 3776-84, CrossRef.

Singh M, Jadhav HR. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discov Today. 2018; 23(3): 745-53, CrossRef.

Semadhi MP, Prasojo SL, Widarini A. Lung cancer: Biomarkers, tyrosine kinase inhibitors and monoclonal antibodies. Mol Cell Biomed Sci. 2017; 1(2): 41-9, CrossRef.

Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res Treat. 2019; 51(2): 502-9, CrossRef.

Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(13): 3908-14, CrossRef.

Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis. J Clin Oncol. 2015; 33(17): 1958-65, CrossRef.

Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006; 66(16): 8163-71, CrossRef.

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689): 446-54, CrossRef.

Yang CY, Yang JCH, Yang PC. Precision management of advanced non–small cell lung cancer. Annu Rev Med. 2020; 71(1): 117-36, CrossRef.

Abdollah NA, Mohamad Safiai NI, Ahmad MK, Das KT, Abdul Razak SR. Suppression of miR130a-3p using CRISPR/Cas9 induces proliferation and migration of non-small cell lung cancer cell line. Indones Biomed J. 2021; 13(4): 364-74, CrossRef.

Kuo CH, Lin SM, Lee KY, Chung FT, Hsieh MH, Fang YF, et al. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer. 2010; 11(1): 51-6, CrossRef.

Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA. 2008; 105(6): 2070-5, CrossRef.

Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006; 118(2): 257-62, CrossRef.

Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3): 169-81, CrossRef.

Huang YH, Hsu KH, Tseng JS, Chen KC, Hsu CH, Su KY, et al. The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Cancer Res Treat. 2018; 50(4): 1294-303, CrossRef.

Chang JW, Huang C, Fang Y, Chang C, Yang C, Kuo CS, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients. Thorac Cancer. 2022; 13(13): 1888-97, CrossRef.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018; 4(11): 1527-34, CrossRef.

Berry DK, Wang X, Michalski ST, Kang HC, Yang S, Creelan BC, et al. Clinical cohort analysis of germline EGFR T790M demonstrates penetrance across ethnicities and races, sexes, and ages. JCO Precis Oncol. 2020; 4: PO.19.00297, CrossRef.

Sonobe S, Taniguchi Y, Saijo N, Naoki Y, Tamiya A, Omachi N, et al. The efficacy of a reduced dose (40mg) of osimertinib with T790M-positive advanced non-small-cell lung cancer. Ann Oncol. 2017; 28(Suppl 10): X130, CrossRef.

Hinkal G, Donehower LA. Decline and fall of the tumor suppressor. Proc Natl Acad Sci USA. 2007; 104(47): 18347-8, CrossRef.

Yamamoto H, Yatabe Y, Toyooka S. Inherited lung cancer syndromes targeting never smokers. Transl Lung Cancer Res. 2018; 7(4): 498-504, CrossRef.

Lu S, Yu Y, Li Z, Yu R, Wu X, Bao H, et al. EGFR and ERBB2 germline mutations in Chinese lung cancer patients and their roles in genetic susceptibility to cancer. J Thorac Oncol. 2019; 14(4): 732-6, CrossRef.

Hou D, Li W, Wang S, Huang Y, Wang J, Tang W, et al. Different clinicopathologic and computed tomography imaging characteristics of primary and acquired EGFR T790M mutations in patients with non-small-cell lung cancer. Cancer Manag Res. 2021; 13: 6389-401, CrossRef.

Wang S, Yan B, Zhang Y, Xu J, Qiao R, Dong Y, et al. Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation. Int J Cancer. 2019; 144(11): 2880-6, CrossRef.

Yu X, Si J, Wei J, Wang Y, Sun Y, Jin J, et al. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study. Cancer Med. 2023; 12(5): 5630-8, CrossRef.

DOI: https://doi.org/10.18585/inabj.v15i5.2431

Copyright (c) 2023 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Indexed by:






The Prodia Education and Research Institute